CIK 0001422143
- Non-accelerated filer
- Smaller reporting company
Kura Oncology, Inc.
Sign in to watch- Ticker
- KURA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 611547851
- Phone
- +1 858-500-8800
- Business address
- 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA, 92121
- Former names
- ZETA ACQUISITION CORP III
- 4 Open-market sale Chief Scientific Officer sold 23,726 shares at $9.78 ($231,931)
- 4 Open-market sale Director sold 10,000 shares at $10.98 ($109,764)
- 4 Planned sale Chief Legal Officer sold 8,804 shares at $11.18 ($98,401)
- 4 Grant or award President and CEO acquired 182,500 shares (grant or award)
- 4 Open-market sale Chief Commercial Officer sold 8,887 shares at $11.18 ($99,329)
- 4 Open-market sale Chief Medical Officer sold 15,485 shares at $11.18 ($173,074)
- 4 Open-market sale SVP, Finance & Accounting sold 4,539 shares at $11.18 ($50,732)
- 4 Planned sale Chief Operating Officer sold 6,902 shares at $11.18 ($77,143)
- 4 Open-market sale Chief Commercial Officer sold 8,891 shares at $8.94 ($79,505)
- 4 Planned sale Chief Legal Officer sold 8,805 shares at $8.94 ($78,736)
- 4 Planned sale Chief Operating Officer sold 6,892 shares at $8.94 ($61,630)
- 4 Open-market sale Chief Medical Officer sold 12,314 shares at $8.94 ($110,114)
- 4 Open-market sale President and CEO sold 36,615 shares at $8.94 ($327,419)
- 4 Open-market sale SVP, Finance & Accounting sold 4,541 shares at $8.94 ($40,607)
- 4 Open-market buy President & CEO bought 50,000 shares at $8.20 ($410,145)
- 4 Open-market buy President and CEO bought 50,000 shares at an average $6.06 ($303,201)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 3 of 14 · 276 filings